Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Misonix Inc. (MSON) -- Ignore unavailable to you. Want to Upgrade?

To: Wesley0428 who wrote (607)	1/17/1998 6:39:00 PM
From: David S.	Respond to of 947

2 truths - I was the person who mentioned the Paresi patents were evaluated by MSON before MNTR bought, which indicates the MSON thought they were as valuable as a rat's ass but it is also true that the amount of prior art is significant, so both factors would suggest that the MNTR attempt should not work. If the legal efforts of MNTR are judged to be a nuisance, can MSON countersue for triple damanges? Perhaps an attorney who is lurking can comment. I am not an attorney, but I make great burgers at Johnny Rockets at 3rd and Main.

To: Wesley0428 who wrote (607)	1/17/1998 7:58:00 PM
From: johne	Read Replies (1) \| Respond to of 947

In the 1997 annual report it is mentioned that the company settled a dispute with two individuals who claimed that they,together with the company's founder,were joint inventors of the technology covered under the patent for liposuction method and apparatus.The company is now paying 5% of all net sales and royalties by the company from this technology,including those received from the MDA license. It would seem they should be brought into the suit to defend their patents that we are paying 5% for.